Quote:

---

I would buy into this if you can point to a company with a single drug collecting revenue for one application anywhere paying a dividend...once Leronlimab is bringing in Billions for 3 or 4 applications perhaps but that is far drown the line

---

Jeff, I don't want to argue my position too strenuously since its starting point is a tale told by a stout red-cheeked bewhiskered uncle who's had too much to drink on a winter's eve -- Respert, maybe. But we all know Cytodyn is a unicorn. After all, how many companies HAVE just a single drug that collects billions in revenue (okay, SIGA does, but not $7 billion; even so, SIGA is being pushed by analysts to fork over a dividend). Cytodyn at that $7 billion point would not only have the one application, but the likelihood of many more. So they'd be looking at a very happy ending to that tale. Goodnight, child, and may you sleep deep and well.